Supplementary Figure S1 from Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer

作者：Darren Cowzer, Henry S. Walch, Pranita Atri, Farheen Shah, Risha Huq, Rohit Thummalapalli, Fatema Nagib, Anna M. Varghese, Danny N. Khalil, Wungki Park, Benoı̂t Rousseau, Andrea Cercek, Joseph Patrick Erinjeri, Randy Yeh, Richard Kinh Gian, Olca Baştürk, Jinru Shia, Debyani Chakravarty, Michael F. Berger, Nikolaus D. Schultz, Mithat Gönen, Eileen Mary O'Reilly, William R. Jarnagin, Ghassan K. Abou‐Alfa, David B. Solit, Walid Khaled Chatila, James J. Harding · 年份：2026 · DOI：10.1158/1078-0432.33776375 · 研究领域：Medicine、Internal medicine、Oncology、Gastroenterology

Supplemental Figure 1: Consort diagram depicting patient/sample exclusions. Untreated groups are at an alteration level, where patients harboring the specific alteration are included in the groups; patients can be in more than one untreated group. Treatment groups are determined by the matched therapy that the patient received.